Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease
- PMID: 15231660
- DOI: 10.1158/0008-5472.CAN-03-3851
Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease
Abstract
The osteolytic bone destruction associated with breast cancer skeletal metastases represents a serious and incurable clinical condition. However, the molecular mechanisms regulating tumor cell expression of factors involved in the generation of osteolytic disease remain elusive. We demonstrated recently that breast cancer cells express the Runx2 transcription factor, essential for bone formation and a regulator of skeletal homeostasis. Our experimental results demonstrate that perturbation of Runx2 regulatory function in tumor cells abolishes their ability to form osteolytic lesions in vivo. In vitro, we show that breast cancer cells inhibit osteoblast differentiation while concurrently enhancing osteoclast differentiation in marrow stromal cell cultures. Disruption of Runx2 activity abrogates both of these cancer cell-mediated effects on bone cells. These results demonstrate that Runx2 expression in breast cancer cells provides a molecular phenotype that enables the interactions between tumor cells and the bone microenvironment that lead to osteolytic disease.
Similar articles
-
Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.Cancer Res. 2007 May 1;67(9):4157-63. doi: 10.1158/0008-5472.CAN-06-2355. Cancer Res. 2007. PMID: 17483326
-
A role for Runx2 in normal mammary gland and breast cancer bone metastasis.J Cell Biochem. 2005 Oct 15;96(3):484-9. doi: 10.1002/jcb.20557. J Cell Biochem. 2005. PMID: 16052475 Review.
-
Nuclear factor-kappaB-dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone.Cancer Res. 2005 Apr 15;65(8):3209-17. doi: 10.1158/0008-5472.CAN-04-4017. Cancer Res. 2005. PMID: 15833852
-
Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.Am J Pathol. 2007 Jan;170(1):160-75. doi: 10.2353/ajpath.2007.051276. Am J Pathol. 2007. PMID: 17200191 Free PMC article.
-
Molecular mechanisms of tumor-bone interactions in osteolytic metastases.Crit Rev Eukaryot Gene Expr. 2000;10(2):159-78. Crit Rev Eukaryot Gene Expr. 2000. PMID: 11186331 Review.
Cited by
-
Roles of RUNX in Hippo Pathway Signaling.Adv Exp Med Biol. 2017;962:435-448. doi: 10.1007/978-981-10-3233-2_26. Adv Exp Med Biol. 2017. PMID: 28299672 Free PMC article. Review.
-
Runt-related transcription factors in human carcinogenesis: a friend or foe?J Cancer Res Clin Oncol. 2023 Sep;149(11):9409-9423. doi: 10.1007/s00432-023-04769-0. Epub 2023 Apr 21. J Cancer Res Clin Oncol. 2023. PMID: 37081242 Free PMC article. Review.
-
YTHDF2-mediated FGF14-AS2 decay promotes osteolytic metastasis of breast cancer by enhancing RUNX2 mRNA translation.Br J Cancer. 2022 Dec;127(12):2141-2153. doi: 10.1038/s41416-022-02006-y. Epub 2022 Oct 10. Br J Cancer. 2022. PMID: 36216883 Free PMC article.
-
Mitotic retention of gene expression patterns by the cell fate-determining transcription factor Runx2.Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3189-94. doi: 10.1073/pnas.0611419104. Epub 2007 Feb 20. Proc Natl Acad Sci U S A. 2007. PMID: 17360627 Free PMC article.
-
RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms.Pancreas. 2011 May;40(4):627-33. doi: 10.1097/MPA.0b013e3182152bda. Pancreas. 2011. PMID: 21499216 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical